User:Mr. Ibrahem/Acute myeloid leukemia
| Acute myeloid leukemia | |
|---|---|
| Other names | Acute myelogenous leukemia, acute nonlymphocytic leukemia (ANLL), acute myeloblastic leukemia, acute granulocytic leukemia[1] |
 | |
| Bone marrow aspirate showing acute myeloid leukemia, arrows indicate Auer rods | |
| Specialty | Hematology, oncology |
| Symptoms | Feeling tired, shortness of breath, easy bruising and bleeding, increased risk of infection[1] |
| Usual onset | All ages, most frequently ~65–75 years old[2] |
| Risk factors | Smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, benzene[1] |
| Diagnostic method | Bone marrow aspiration, blood test[3] |
| Treatment | Chemotherapy, radiation therapy, stem cell transplant[1][3] |
| Prognosis | Five-year survival ~27% (US)[2] |
| Frequency | 1 million (2015)[4] |
| Deaths | 147,100 (2015)[5] |
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production.[1] Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection.[1] Occasionally, spread may occur to the brain, skin, or gums.[1] As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.[1][6]
Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene.[1] The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells.[1] Diagnosis is generally based on bone marrow aspiration and specific blood tests.[3] AML has several subtypes for which treatments and outcomes may vary.[1]
AML typically is initially treated with chemotherapy, with the aim of inducing remission.[1] People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant.[1][3] The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive.[3]
In 2015, AML affected about one million people and resulted in 147,000 deaths globally.[4][5] It most commonly occurs in older adults.[2] Males are affected more often than females.[2] Five-year survival rate are about 35% in people under 60 years old and 10% in people over 60 years old.[3] Older people whose health is too poor for intensive chemotherapy have a typical survival of 5–10 months.[3] It accounts for roughly 1.8% of cancer deaths in the United States.[2]
References[edit]
- ^ a b c d e f g h i j k l m "Adult Acute Myeloid Leukemia Treatment". National Cancer Institute. 6 March 2017. Archived from the original on 23 October 2018. Retrieved 19 December 2017.
- ^ a b c d e "Acute Myeloid Leukemia – Cancer Stat Facts". NCI. Archived from the original on 28 July 2017. Retrieved 10 May 2017.
- ^ a b c d e f g Döhner H, Weisdorf DJ, Bloomfield CD (September 2015). "Acute Myeloid Leukemia". The New England Journal of Medicine. 373 (12): 1136–52. doi:10.1056/NEJMra1406184. PMID 26376137. S2CID 40314260.
- ^ a b "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. October 2016. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- ^ a b "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. October 2016. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- ^ Marino, Bradley S.; Fine, Katie S. (2013). Blueprints Pediatrics. Lippincott Williams & Wilkins. p. 205. ISBN 9781451116045. Archived from the original on 27 August 2021. Retrieved 25 May 2020.